

CHINA CROSSROADS

Tuesday, July 2nd, 2024, 19:30 – 21:00

Book Talk on Biopharma in China: Innovation, Trends, Dealmaking

Ben Wu

Healthcare Partner at Agio Capital

Author of [Biopharma in China](#) (2024)

Founding CEO of Citrine Medicine

Former Rare Diseases Head at CANbridge Pharma

WhiteSpace | Jianing Building 5F | 500 Yanan Xi Lu
200rmb admission with drink | FREE for members
RSVP to Frank Tsai at editor@shanghai-review.org



[Biopharma in China](#) (2024) provides an insider's overview of the emerging Chinese biopharma sector, its dynamics and trends, first bust and boom cycle, long-term perspectives, and how as a foreign company or investor to tap into this. China has gone from a country with no innovation in drug discovery, to a country which starts to out-license its biopharma technology to the rest of the world. The Chinese biopharma sector is only a decade old, but it already has become a new driver of growth and value. The book takes a closer look at what drives Chinese innovation in the biopharma sector, how to deal with this innovation, and what opportunities and challenges this provides for foreign companies. The book also takes a deep dive into its first biopharma boom and bust cycle, and what it means for the sector. It also explains what deals Chinese biopharma companies and investors are looking for, what works and what doesn't, and how as a foreign company can tap into the world's second largest healthcare market.

[Ben Wu](#) is Healthcare Partner at Agio Capital, a Belgium based advisory firm operating both in Europe and China. He has 30 years of experience in the biopharma industry, holding various senior executive positions in the Asia Pacific region. Immediately prior to joining Agio Capital, Mr. Wu was the founding CEO of Citrine Medicine from 2019 to 2021 to make therapies for rare diseases available and accessible to patients in China. Prior to joining Citrine Medicine, Mr. Wu was the Head of Rare Diseases at CANbridge Pharmaceuticals (1228.HK) from 2017-2019 responsible for establishing the company's rare disease unit to become a leading rare disease company in China. Mr. Wu first joined Sanofi-Genzyme in 2008 to pioneer the company's efforts in expanding into Hong Kong, Southeast Asia, Taiwan and China. Mr. Wu was the general manager at Sanofi-Genzyme in China from 2012 to 2015. Prior to joining Genzyme, Mr. Wu spent over 14 years at Johnson & Johnson. Mr. Wu is a registered pharmacist in Canada and holds an MBA from the University of British Columbia.

[China Crossroads](#) hosts talks on all topics related to China, including business, foreign policy, and other areas as they relate to China, the idea being that China is both already a "crossroads" of the world and itself at a "crossroads" in terms of its future global influence. For more information, contact Frank Tsai at editor@shanghai-review.org.